Key Takeaways Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Shares of Novo Nordisk slipped in Monday morning trading ... which combines the GLP-1 agonist semaglutide, the active ingredient in Wegovy and Ozempic, and a cagrilintide, a synthetic version ...